Atty. Dkt. No. 072121-0366

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Jayesh VORA et al.

Title: METHODS OF TREATING CANCER AND RELATED METHODS

Appl. No.: 10/706,328

Filing Date: 11/12/2003

Examiner: Unknown

Art Unit: Unknown

CERTIFICATE OF MAILING
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450, on the date below.

Bernard P. Friedrichsen
(Printed Name)

(Signature)

December 10, 2003
(Date of Deposit)

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.56

Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450

Sir:

Submitted herewith on Form PTO-1449 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR § 1.56. A copy of each listed document, except as noted below, is being submitted to comply with the provisions of 37 CFR § 1.97 and § 1.98.

The USPTO has waived the requirement under 37 CFR § 1.98(a)(2)(i) to submit copies of U.S. patents and U.S. patent application publications when citing and submitting an Information Disclosure Statements in a patent application filed after June 30, 2003 and in an international application that has entered the national stage under 37 USC § 371 after June 30, 2003. Therefore, copies of these types of documents are not being supplied in connection with this application although they are listed in the accompanying Form PTO-1449.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in

37 CFR § 1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR § 1.97(b), within three (3) months of the filing date of the application.

RELEVANCE OF EACH DOCUMENT

An English translation of the foreign-language documents is not readily available. However, an English language abstract of each of the foreign language documents is included.

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO-1449 be returned in accordance with MPEP § 609.

Applicants believe no fee is required for this filing. However, the Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 50-2350. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-2350.

Respectfully submitted,

Date December 10, 2003

By _____

FOLEY & LARDNER
Customer Number: 23524
Telephone: (608) 258-4281
Facsimile: (608) 258-4258

Bernard P. Friedrichsen
Attorney for Applicant
Registration No. 44,689

FORM PTO 1449 (modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary) Date Submitted to PTO: December 10, 2003	DOCKET NO. 072121-0366	SERIAL NO. 10/706,328
	APPLICANTS Jayesh VORA *et al.*	
	FILING DATE November 12, 2003	GROUP Unassigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	5,073,492	Dec. 17, 1991	Chen et al.			
	A2	5,414,088	May 9, 1995	Von Der Saal et al.			
	A3	5,585,380	Dec. 17, 1996	Bianco et al.			
	A4	5,646,153	Jul. 8, 1997	Spada et al.			
	A5	5,710,158	Jan. 20, 1998	Myers et al.			
	A6	5,763,441	Jun. 9, 1998	App et al.			
	A7	5,792,771	Aug. 11, 1998	App et al.			
	A8	5,801,212	Sept. 1, 1998	Okamoto et al.			
	A9	5,855,866	Jan. 5, 1999	Thorpe et al.			
	A10	Re 36,256	Jul. 20, 1999	Spada et al.			
	A11	5,942,385	Aug. 24, 1999	Hirth			
	A12	5,981,569	Nov. 9, 1999	App et al.			
	A13	6,057,320	May 2, 2000	Spada et al.			
	A14	6,258,951	Jul. 10, 2001	Lohmann et al.			
	A15	6,303,600	Oct. 16, 2001	Cox et al.			
	A16	6,306,874	Oct. 23, 2001	Fraley et al.			
	A17	6,313,138	Nov. 6, 2001	Fraley et al.			
	A18	Re 37,650	Apr. 9, 2002	Myers et al.			
	A19	6,420,382	Jul. 16, 2002	Fraley et al.			
	A20	6,479,512	Nov. 12, 2002	Fraley et al.			
	A21	2002/0103230	Aug. 1, 2002	Renhowe et al.			

	A22	2002/0107392	Aug. 8, 2002	Renhowe et al.			
	A23	2003/0028018	Feb. 6, 2003	Renhowe et al.			
	A24	6,605,617	Aug. 12, 2003	Renhowe et al.			
	A25	2003/0158224	Aug. 21, 2003	Renhowe et al.			
	A26	2003/0207883	Nov. 6, 2003	Renhowe et al.			
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	**DATE**	**COUNTRY**	**CLASS**	**SUBCLASS**	**TRANSLATION YES/NO/ OR ABSTRACT**
	A27	2363459	Jun. 26, 1975	Germany			
	A28	3634066	Apr. 21, 1988	Germany			
	A29	19841985	Mar. 9, 2000	Germany			
	A30	0 290 153	Nov. 9, 1998	Europe			
	A31	0 509 717	Apr. 10, 1992	Europe			
	A32	0 508 800	Oct. 14, 1992	Europe			
	A33	0 747 771	Dec. 11, 1996	Europe			
	A34	0 797 376	Sept. 24, 1997	Europe			
	A35	1 086 705	Mar. 28, 2001	Europe			
	A36	6-9952	Jan. 18, 1994	Japan			
	A37	7-43896	Feb. 14, 1995	Japan			
	A38	8-29973	Feb. 2, 1996	Japan			
	A39	63-258903	Oct. 26, 1998	Japan			
	A40	92/18483	Oct. 29, 1992	WO			
	A41	92/20642	Nov. 26, 1992	WO			
	A42	95/15758	Jun. 15, 1995	WO			
	A43	95/18801	Jul. 13, 1995	WO			
	A44	97/03069	Jan. 30, 1997	WO			
	A45	97/34876	Sept. 25, 1997	WO			
	A46	97/48694	Dec. 24, 1997	WO			
	A47	98/13350	Apr. 2, 1998	WO			

	A48	99/10349	Mar. 4, 1999	WO			
	A49	99/50263	Oct. 7, 1999	WO			
	A50	99/65897	Dec. 23, 1999	WO			
	A51	00/27379	May 18, 2000	WO			
	A52	01/02369	Jan. 11, 2001	WO			
	A53	01/28993	Apr. 26, 2001	WO			
	A54	01/29025	Apr. 26, 2001	WO			
	A55	01/52904	Jul. 26, 2001	WO			
	A56	01/55114	Aug. 2, 2001	WO			
	A57	01/62251	Aug. 30, 2001	WO			
	A58	01/62252	Aug. 30, 2001	WO			
	A59	02/18383	Mar. 7, 2002	WO			
	A60	02/22598	Mar. 21, 2002	WO			
	A61	02/32861	Apr. 25, 2002	WO			
	A62	03/004488	Jan. 16, 2003	WO			

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)			
	A63		Aprelikova, O., et al., "FLT4, a novel Class III Receptor Tyrosine Kinase in chromosome 5q33-qter1," *Cancer Res.*, Vol. 52, pp. 746-748, February 1, 1992, published by The American Association for Cancer Research, Stanford University Libraries' High Wire Press, California, United States of America.
	A64		Beals, C. R. et al., "Nuclear Export of NF-ATc Enhanced by Glycogen Synthase Kinase-3," *Science*, Vol. 275, pp. 1930-1933, 28 March 1997.
	A65		Brownlees, J. et al., "Tau phosphorylation in transgenic mice expressing glycogen synthase kinase-3β transgenes," *NeuroReport*, Vol. 8, No. 15, pp. 3251-3255, 20 October 1997; published by Rapid Science Publishers.
	A66		Chan, T. A. et al., "14-3-3σ is required to prevent mitotic catastrophe after DNA damage," *Nature*, Vol. 401, pp. 616-620, 7 October 1999; published by Macmillan Magazines Ltd.
	A67		Chen, G. et al., "The Mood-Stabilizing Agent Valproate Inhibits the Activity of Glycogen Synthase Kinase-3," *J. Neurochem.*, Vol. 72, No. 3, 1999, pp. 1327-1330; published by Lippincott Williams & Wilkins, Inc., Philadelphia.
	A68		Chesi, M. et al., "Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma," *Blood*, Vol. 97, No. 3, pp. 729-736, 1 February 2001; published by The American Society of Hematology.
	A69		Connolly, D., et al., "Human Vascular Permeability Factor," *J. Biol. Chem.*, Vol. 264, pp. 20017-20024, 1989, published by The American Society For Biochemistry and Molecular Biology, Inc., Stanford University Libraries' High Wire Press, California, United States of America.
	A70		Connolly, D., et al., "Tumor Vascular Permeability Factor Stimulates Endothelial Cell Growth and Angiogenesis," *J. Clin. Invest.*, Vol. 84, pp. 1470-1478, November, 1989, published by The American Society for Clinical Investigation, Inc., Stanford University Libraries' High Wire Press, California, United States of America.
	A71		Cross, A. E. et al., "The inhibition of glycogen synthase kinase-3 by insulin or insulin-like growth factor 1 in the rat skeletal muscle cell line L6 blocked by wortmannin, but not by rapamycin: evidence that wortmannin blocks activation of the mitogen-activated protein kinase pathway in L6 cells between Ras and Raf," *Biochem J.*, Vol. 303, pp. 21-26, 1994; (printed in Great Britain).

	A72		DeVries, C., et al., "The fms-Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth Factor," *Science*, Vol. 255, pp. 989-991, February 21, 1992, published by The American Society for the Advancement of Science, Stanford University Libraries' High Wire Press, California, United States of America.
	A73		Doukas, M. A. et al., "Effect of Lithium on Stem Cell and Stromal Cell Proliferation in vitro," *Exp. Hematol.*, Vol. 14, pp. 215-221, 1986; published by International Society for Experimental Hematology.
	A74		Ferrara, N., et al., "The Biology of Vascular Endothelial Growth Factor," *Endocrinol. Rev.*, Vol. 18, No. 1, pp. 4-25, 1997, published by The Endocrine Society, Stanford University Libraries' High Wire Press, California, United States of America.
	A75		Flückiger-Isler, R. E. et al., "Stimulation of rat liver glycogen synthesis by the adenosine kinase inhibitor 5-iodotubercidin," *Biochem. J.*, Vol. 292, pp. 85-91, 1993; (printed in Great Britain).
	A76		Folkman, J., "Fighting Cancer by Attacking Its Blood Supply," *Scientific American*, Vol. 275, pp. 150-154, September, 1996, published by Scientific American, Inc., New York, New York, United States of America.
	A77		Hammond, W. P. et al., "Lithium Therapy of Canine Cyclic Hematopoiesis," *Blood*, Vol. 55, No. 1, pp. 26-28, January, 1980.
	A78		Heinrich, M. C. et al., "Inhibition of KIT Tyrosine Kinase Activity: A Novel Molecular Approach to the Treatment of KIT-Positive Malignancies," *J. Clin. Oncol.*, Vol. 20, No. 6, pp. 1692-1703, March 15, 2002.
	A79		Hennequin, L. F., et al., "Design and Structure – Activity Relationship of a New Class of Potent VEGF Receptor Tyrosine Kinase Inhibitors,: *J. Med. Chem.*, Vol. 42, No. 26, pp. 5369-5389, 1999; published by American Chemical Society, Washington, D.C.
	A80		Hirao, A. et al., "DNA Damage-Induced Activation of p53 by the Checkpoint Kinase CHk2," *Science*, Vol. 287, pp. 1824-1827, 10 March 2000.
	A81		Klein, P. S. et al., "A molecular mechanism for the effect of lithium on development," *Proc. Natl. Acad. Sci. USA*, Vol. 93, pp. 8455-8459, August 1996.
	A82		Lee, J. et al., "Positive Regulation of Wee1 by Chk1 and 14-3-3 Proteins," *Molecular Biology of the Cell*, Vol. 12, pp. 551-563, March 2001; published by The American Society for Cell Biology.
	A83		Leung, D., et al., "Vascular Endothelial Growth Factor Is a Secreted Angiogenic Mitogen," *Science*, Vol. 246, pp. 1306-1309, December 8, 1989, published by The American Society for the Advancement of Science, Stanford University Libraries' High Wire Press, California, United States of America.
	A84		Levis, M. et al., "A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo," *Blood*, Vol. 99, No. 11, pp. 3885-3891, 1 June 2002; published by the American Society of Hematology.
	A85		Liu, Q. et al., "Chk1 is an essential kinase that is regulated by Atr and required for the G_2/M DNA damage checkpoint," *Genes & Development*, Vol. 14, 2000, pp. 1448-1459; published by Cold Springs Harbor Laboratory Press.
	A86		Lopez-Girona, A. et al., "Nuclear localization of Cdc25 is regulated by DNA damage and a 14-3-3 protein," *Nature*, Vol. 397, pp. 172-175, 14 January 1999; published by Macmillan Magazines Ltd.
	A87		Lovestone, S. et al., "Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells," *Current Biology*, Vol. 4, pp. 1077-1086, 1 December 1994; published by Elsevier Science Ltd.
	A88		Lymboussaki, A., "Vascular endothelial growth factors and their receptors in embryos, adults, and in tumors," Academic Dissertation, University of Helsinki, Molecular/Cancer Biology Laboratory and Department of Pathology, Haartman Institute, 1999.
	A89		Maguire, M.P., et al., "A New Series of PDGF Receptor Tyrosine Kinase Inhibitors: 3-Substituted Quinoline Derivatives," *J. Med. Chem.*, Vol. 37, No. 14, pp. 2129-2137, 1994; published by American Chemical Society, Washington, D.C.
	A90		Massillon, D. et al., "Identification of the glycogenic compound 5-iodotubercidin as a general protein kinase inhibitor," *Biochem. J.*, Vol. 299, pp. 123-128, 1994; printed in Great Britain.
	A91		Matei, S., et al., "Condensation of ethyl 2-benzimidazoleacetate with carbonyl compounds," *Rev. Chim.*, Vol. 33, No. 6, pp. 527-530, 1989, published by the Central Institute of Chemistry, Bucharest, Romania.
	A92		Mustonen, T., et al., "Endothelial Receptor Tyrosine Kinases Involved in Angiogenesis," *J. Cell Biology*, Vol. 129, No. 4, pp. 895-898, May, 1995, published by The Rockfeller University Press, New York, New York, United States of America.
	A93		Nonaka, S. et al., "Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-D-aspartate receptor-mediated calcium influx," *Proc. Natl. Acad. Sci. USA*, Vol. 95, pp. 2642-2647, March 1998.
	A94		Parker, L. L. et al., "Inactivation of the p34cdc2-Cyclin B Complex by the Human WEE1 Tyrosine Kinase," *Science*, Vol. 257, pp. 1955-1957, 25 September 1992.

	A95		Pei, J.-J. et al., "Distribution, Levels, and Activity of Glycogen Synthase Kinase-3 in the Alzheimer Disease Brain," *Journal of Neuropathology and Experimental Neurology,"* Vol. 56, No. 1, pp. 70-78, January, 1997; published by the American Association of Neuropathologists.
	A96		Peng, C.-Y. et al., "Mitotic and G_2 Checkpoint Control: Regulation of 14-3-3 Protein Binding by Phosphorylation of Cdc25C on Serine-216," *Science*, Vol. 277, pp. 1501-1505, 5 September 1997.
	A97		Plouet, J., et al., "Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT-20 cells," *EMBO J.*, Vol. 8, No. 12, pp. 3801-3806, 1989, published by IRL Press.
	A98		Quinn, T., et al., "Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium," *Proc. Natl. Acad. Sci. USA*, Vol. 90, pp. 7533-7537, August, 1993.
	A99		Saito, Y. et al., "The mechanism by which epidermal growth factor inhibits glycogen synthase kinase 3 in A431 cells," *Biochem. J.*, Vol. 303, pp. 27-31, 1994; printed in Great Britain.
	A100		Sanchez, Y. et al., "Conservation of the Chk1 Checkpoint Pathway in Mammals: Linkage of DNA Damage to Cdk Regulation Through Cdc25," *Science*, Vol. 277, pp. 1497-1501, 5 September 1997.
	A101		Shibuya, M., et al., "Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family," *Oncogene*, Vol. 5, pp. 519-524, 1990, published by Macmillan Press Ltd., Stockton Press Company, Great Britain.
	A102		Smolich, B.D. et al., "The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts," *Blood*, Vol. 97, No. 5, pp. 1413-1421, 1 March 2001; published by The American Society of Hematology.
	A103		Stambolic, V. et al., "Lithium inhibits glycogen synthase kinase-3 activity and mimics Wingless signaling in intact cells," *Current Biology*, Vol. 6, No. 12, pp. 1664-1668, 1996; published by Current Biology Ltd. ISSN 0960-9822.
	A104		Stover, D. R., "Recent advances in protein kinase inhibition: Current molecular scaffolds used for inhibitor synthesis," *Current Opinion in Drug Discovery & Development*, Vol. 2, No. 4, pp. 274-285, 1999; published by PharmaPress Ltd., London, United Kingdom.
	A105		Sun, T-Q. et al.. "PAR-1 is a Dishevelled-associated kinase and a positive regulator of Wnt signalling," *Nature Cell Biology*, Vol. 3, pp. 628-636, July 2001; published by Macmillan Magazines Ltd.
	A106		Takashima, A. et al., "tau protein kinase I is essential for amyloid β-protein-induced neurotoxicity," *Proc. Natl. Acad. Sci. USA*, Vol. 90, pp. 7789-7793, August 1993.
	A107		Takashima, A. et al., "Presenilin 1 associates with glycogen synthase kinase-3β and its substrate tau," *Proc. Natl. Acad. Sci. USA*, Vol. 95, pp. 9637-9641, August 1998; published by The National Academy of Sciences.
	A108		Terman, B., et al., "Identification of a new endothelial cell growth factor receptor tyrosine kinase," *Oncogene*, Vol. 6, pp. 1677-1683, 1991, published by Macmillan Press Ltd., Stockton Press Company, Great Britain.
	A109		Thomas, M.D., R. J. et al., "Progress in Geriatrics: Excitatory Amino Acids in Health and Disease," *J. of the American Geriatrics Society,"* Vol. 43, No. 11, November 1995; published by American Geriatrics Society.
	A110		Ukrainets, I., "Effective Synthesis of 3-(Benzimidazol-2-yl)-4-Hydroxy-2-Oxo-1,2-Dihydroquinolines," *Tet. Lett.*, Vol. 36, No. 42, pp. 7747-7748, 1995, published by Elsevier Science Ltd., Great Britain.
	A111		Ukrainets, I., et al., "2-Carbethoxymethyl-4H-3,1-Benzoxazin-4-One. 3.*Condensation of o-Phenylenediamine," pp. 198-200, translated from *Khimiya Geterotsiklicheskikh Soedinii*, No. 2, pp. 239-241, February, 1992, published by Plenum Publ. Corp., London, Great Britain.
	A112		Ukrainets, I., et al., "4-Hydroxy-2-Quinolones 7.* Synthesis and Biological Properties of 1-R-3-(2-Benzimidazolyl)-4-Hydroxy-2-Quinolones," pp. 92-94, translated from *Khimiya Geterotsiklicheskikh Soedinii*, No. 1, pp. 105-108, January, 1993, published by Plenum Publ. Corp., London, Great Britain.
	A113		Ukrainets, I., et al., "4-Hydroxy-2-Quinolones. 16.* Condensation of N-R-Substituted Amides of 2-Carboxy-Malonanilic Acid With o-Phenylenediamine," pp. 941-944, translated from *Khimiya Geterotsiklicheskikh Soedinii*, Vol. 8, pp. 1105-1108, August, 1993, published by Plenum Publ. Corp., London, Great Britain.
	A114		Ukrainets, I., et al., "4-Hydroxy-2-Quinolones. 32.* Synthesis and Antithyroid Activity of Thio Analogs of 1H-2-OXO-3-(2-Benzimidazolyl)-4-HydroxyQuinoline," *Chem. Heterocyclic Comp.*, Vol. 33, No. 5, pp. 600-604, 1997, published by Kluwer Academic Publishers, London, Great Britain.
	A115		Ullrich, A., et al., "Signal Transduction by Receptors with Tyrosine Kinase Activity," *Cell*, Vol. 61, pp. 203-212, April 20, 1990, published by Cell Press, Cambridge, Massachusetts, United States of America.

/	A116		van der Geer, P., et al., "Receptor Protein-Tyrosine Kinases and Their Signal Transduction Pathways," *Annu. Rev. Cell Biol.*, Vol. 10, pp. 251-337, 1994, published by Annual Reviews, Inc., Palo Alto, California, United States of America.
/	A117		Vogelstein, B. et al., "Surfing the p53 network," *Nature*, Vol. 408, pp. 307-310, 16 November 2000; published by Macmillan Magazines Ltd.
/	A118		Welsh, G. I. et al., "Glycogen synthase kinase-3 is rapidly inactivated in response to insulin and phosphorylates eukaryotic initiation factor eIF-2B," *Biochem. J.*, Vol. 294, pp. 625-629, 1993; printed in Great Britain.
/	A119		Yamasaki, Y. et al., "Pioglitazone (AD-4833) Ameliorates Insulin Resistance in Patients with NIDDM," *Tohoku J. Exp. Med.*, Vol. 183, pp. 173-183, 1997.
/	A120		Zhao, H. et al., "ATR-Mediated Checkpoint Pathways Regulate Phosphorylation and Activation of Human Chk1," *Molecular and Cellular Biology*, Vol. 21, No. 13, pp. 4129-4139, July 2001; published by American Society for Microbiology.
/	A121		Zhang, Z. et al., "Destabilization of β-catenin by mutations in presenilin-1 potentiates neuronal apoptosis," *Nature*, Vol. 395, pp. 698-702, 15 October 1998; published by Macmillan Publishers Ltd.
/	A122		List of compounds purchased from various vendors (3 pages).
/	A123		CAS printout for 304876-79-7 Registry File, entry date into Registry File November 29, 2000.
/	A124		CAS printout for 300591-52-0 Registry File, entry date into Registry File October 31, 2000.

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to Applicant.